Avadel CNS Pharmaceuticals LLCSeptember 12, 2025

FDA 483 - Avadel CNS Pharmaceuticals LLC - September 12, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Avadel CNS Pharmaceuticals LLC

Record Details

Avadel CNS Pharmaceuticals LLC, located in Chesterfield, MO, was inspected regarding its Risk Evaluation and Mitigation Strategy (REMS) program. The inspection revealed that the firm failed to comply with its approved REMS audit plan and schedule. Specifically, several certified pharmacies were audited outside the required 90-day initial timeframe or the annual audit timeframe for the drug Lumryz.

Company: Avadel CNS Pharmaceuticals LLC
Inspection Date: September 12, 2025
Product Type: Drugs
Office: Kansas City District Office
Person: Courtney R. Bratina (issuing_officer)

Open in Dashboard

ID · 463e5c07-8816-4d91-a81e-150cf522a6db